Growth Metrics

Merck (MRK) EBT Growth (3y) (2012 - 2026)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Growth (3y) (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn 79.52%
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn 88.09%
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn 29.81%
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn -43.56%
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn -15.40%
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn 25.67%
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn -20.34%
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn 5.36%
10 Gsk 88.34 Bn 83.66 Bn - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -43.56%
Dec 31, 2025 -0.89%
Sep 30, 2025 23.47%
Jun 30, 2025 3.67%
Mar 31, 2025 6.69%
Dec 31, 2024 2.18%
Sep 30, 2024 -8.08%
Jun 30, 2024 51.80%
Mar 31, 2024 23.82%
Dec 31, 2023 7.02%
Sep 30, 2023 27.59%
Jun 30, 2023 -57.86%
Mar 31, 2023 -1.66%
Dec 31, 2022 63.10%
Sep 30, 2022 15.14%
Jun 30, 2022 11.25%
Mar 31, 2022 16.59%
Dec 31, 2021 14.50%
Sep 30, 2021 25.49%
Jun 30, 2021 -6.28%
Mar 31, 2021 30.47%
Dec 31, 2020 -49.69%
Sep 30, 2020 138.29%
Jun 30, 2020 3.97%
Mar 31, 2020 24.21%
Dec 31, 2019 -3.47%
Sep 30, 2019 -6.67%
Jun 30, 2019 29.40%
Mar 31, 2019 23.61%
Dec 31, 2018 47.23%
Sep 30, 2018 3.60%
Jun 30, 2018 37.24%
Mar 31, 2018 -0.88%
Dec 31, 2017 -45.81%
Sep 30, 2017 -48.80%
Jun 30, 2017 8.85%
Mar 31, 2017 -1.42%
Dec 31, 2016 -45.92%
Sep 30, 2016 23.71%
Jun 30, 2016 6.50%
Mar 31, 2016 1.57%
Dec 31, 2015 -15.11%
Sep 30, 2015 2.62%
Jun 30, 2015 -32.97%
Mar 31, 2015 -18.03%
Dec 31, 2014 95.49%
Sep 30, 2014 -14.12%
Jun 30, 2014 4.19%
Mar 31, 2014 6.54%
Dec 31, 2013 38.56%
Sep 30, 2013 45.22%
Jun 30, 2013 0.11%
Mar 31, 2013 33.94%
Dec 31, 2012 -53.15%
Sep 30, 2012 53.60%
Jun 30, 2012 51.35%
Mar 31, 2012 30.42%